Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment

International Journal of Clinical Practice

Volumn 68, Issue 1, 2014, Pages 104-110

  Wettermark, B ^a,b   Brandt, L ^a   Kieler, H ^a   Boden R ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; OPIATE; PREGABALIN; PSYCHOTROPIC AGENT; SEDATIVE AGENT; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT;

ADD ON THERAPY; ADULT; ARTICLE; DRUG INDICATION; DRUG USE; DRUG UTILIZATION; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PATIENT HISTORY OF THERAPY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SWEDEN; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANXIETY DISORDERS; CLINICAL PRACTICE; MEDICATION COMPLIANCE; MIDDLE AGED; NEURALGIA;

ANALGESICS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY DISORDERS; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEURALGIA; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84890564504     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12182     Document Type: Article

References (30)

1. Tassone DM, Boyce E, Guyer J, Nuzum D,. Pregabalin: a novel 7-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29: 27-48.
2. European Medicines Agency (EMA). Lyrica: EPAR-Product Information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000546/WC500046602.pdf [accessed March 2013].
3. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ,. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; CD007076.
4. Lozsadi D, Hemming K, Marson AG,. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008; CD005612. DOI: 10.1002/14651858.CD005612.pub2.
5. Baldwin DS, Waldman S, Allgulander C,. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2011; 14: 697-710.
6. Montgomery SA,. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006; 7: 2139-54.
7. FDA Approves First Drug for Treating Fibromyalgia (Press release). U.S. Food and Drug Administration. June 2007. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108936.htm [assessed March 2013]
8. Socialstyrelsen. Läkemedel-statistik för år 2009. (National Drug statistics for Sweden 2009). Published March 2010.
9. Wettermark B, Persson ME, Wilking N, et al., for the Regional Drug Expert Consortium. Forecasting drug use and expenditures in a metropolitan health region. BMC Health Serv Res 2010; 10: 128.
10. Aitken M, Berndt ER, Cutler DM,. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood) 2009; 28: w151-60.
11. Statistics Sweden. www.scb.se [accessed March 2013]
12. Ludvigsson J, Otterblad-Olausson P, Pettersson BU, Ekbom A,. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659-67.
13. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT,. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106: 86-94.
14. Wettermark B, Hammar N, Fored M, et al. The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35.
15. Ludvigsson JF, Andersson A, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
16. Bramness JG, Sandvik P, Engeland A, Skurtveit S,. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? a comparison with gabapentin using the norwegian prescription database. Basic Clin Pharmacol Toxicol 2010; 107: 883-6.
17. Oteri A, Trifirò G, Gagliostro MS, et al. Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. Br J Clin Pharmacol 2010; 70: 514-22.
18. UK Department of Health (2010). Extent and Causes of International Variations in Drug Usage: a Report for the Secretary of State for Health. London: COI. Available from: https://www.gov.uk/government/publications/extent- and-causes-of-international-variations-in-drug-usage [assessed April 2013].
19. Andersen G, Vestergaard K, Ingeman NM, et al. Incidence of central post-stroke pain. Pain 1995; 61: 187-93.
20. Osterberg A, Boivie J, Thuomas KA,. Central pain in multiple sclerosis-prevalence and clinical characteristics. Eur J Pain 2005; 9: 531-42.
21. Siddall PJ, McClelland JM, Rutkowski SB, et al. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003; 103: 249-57.
22. Sadosky A, McDermott AM, Brandenburg NA, Strauss M,. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008; 8: 45-56.
23. Kwan P, Sander JW,. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004; 75: 1376-81.
24. Carter RM, Wittchen HU, Pfister H, Kessler RC,. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001; 13: 78-88.
25. Lyrica kvarstår i högkostnadsskyddet med begränsning. (Reimbursement review for Lyrica, in Swedish). Swedish Dental and Pharmaceutical Benefits Board. Stockholm 2012. http://www.tlv.se/lyrica (assessed March 2013)
26. Gore M, Tai K-S, Zlateva G, Bala Chandran A, Leslie D,. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Practice 2011; 11: 528-39.
27. Kozma CM, Benson C, Slaton TL, Kim MS, Vorsanger GJ,. Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy. Curr Med Res Opin 2012; 28: 1485-96.
28. Wong ICK, Chadwick DW, Fenwick PBC, Mawer GE, Sander JWAS,. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 1999; 40: 1439-45.
29. van Hulten R, Isacson D, Bakker A, Leufkens HG,. Comparing patterns of long-term benzodiazepine use between a Dutch and a Swedish community. Pharmacoepidemiol Drug Saf 2003; 12: 49-53.
30. Svarstad BL,. The Doctor-Patient Encounter: an Observational Study of Communication and Outcome [dissertation]. Ann Arbor: University of Wisconsin, 1974.